Merck Delays Migraine Drug Filing; Q1 Sales Fall Short of Analyst Expectations
This article was originally published in The Pink Sheet Daily
Executive Summary
Telcagepant approval, next anticipated opportunity in pipeline, at standstill; analysts look to Schering-Plough deal to bolster Merck sales.
You may also be interested in...
Cervarix, Gardasil Set For FDA Advisory Committee Review
GlaxoSmithKline knew it was in for scrutiny of its novel AS04 adjuvant, but review of Merck's application to make Gardasil gender-neutral could offer backdoor to re-examine the HPV vaccine's safety record.
Cervarix, Gardasil Set For FDA Advisory Committee Review
GlaxoSmithKline knew it was in for scrutiny of its novel AS04 adjuvant, but review of Merck's application to make Gardasil gender-neutral could offer backdoor to re-examine the HPV vaccine's safety record.
Cash-Tight MAP Could Win With Inhaled Migraine Drug
Merck’s switch to backup CGRP after liver-enzyme trouble could provide an edge to MAP Pharmaceuticals.